Investigation of respiratory tract coinfections in Coronavirus disease 2019 infected and suspected cases.
COVID-19
Coinfection
multiplex PCR
Journal
Northern clinics of Istanbul
ISSN: 2536-4553
Titre abrégé: North Clin Istanb
Pays: Turkey
ID NLM: 101684520
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
06
2022
revised:
24
07
2022
accepted:
12
08
2022
entrez:
30
11
2022
pubmed:
1
12
2022
medline:
1
12
2022
Statut:
epublish
Résumé
The aim of our study is to determine the risk of coinfection with COVID-19 due to the high prevalence of viral agents in Istanbul in autumn (September, October, and November) and winter (December and January) and to investigate the effects of age, gender, season and clinical features on the development of coinfection with COVID-19. In the routine studies of our hospital, COVID-19, reverse transcriptase polymerase chain reaction (RTA kit, Turkiye) and Multiplex PCR Bio-Fire (Bio Merieux Company, France) methods were studied from the nasopharyngeal swab sample and the data were recorded. A total of 400 people with a mean age (7.91±17.80) were included in the study by retrospective scanning. Considering the virus distribution, Respiratory syncytial virus (RSV), COVID-19, rhino/entero virus did not show a significant difference in autumn and winter, while H. metapneumovirus, adeno virus, influenza A significantly higher rates were observed in winter months. Parainfluenza (1, 2, 3, 4) and Corona OC43 were detected at a higher rate in autumn compared to other viruses. Double and triple coinfection rates with other viral agents were high for 2 years and younger. The risk of coinfection of COVID-19 with influenza A, RSV, parainfluenza, and rhino/entero virus was found to be higher than other viral agents. Especially in winter, the risk of coinfection with influenza A and COVID-19 increases. In terms of treatment management, coinfection should be investigated in risky patients and influenza a vaccine should be offered to risky groups.
Identifiants
pubmed: 36447585
doi: 10.14744/nci.2022.82608
pii: NCI-9-421
pmc: PMC9677056
doi:
Types de publication
Journal Article
Langues
eng
Pagination
421-428Informations de copyright
© Copyright 2022 by Istanbul Provincial Directorate of Health.
Déclaration de conflit d'intérêts
No conflict of interest was declared by the authors.
Références
Ann Hematol. 2020 Aug;99(8):1945-1946
pubmed: 32447425
IDCases. 2020 Apr 20;20:e00762
pubmed: 32368493
R I Med J (2013). 2020 Mar 19;103(2):75-76
pubmed: 32192233
J Med Virol. 2020 Nov;92(11):2870-2873
pubmed: 32530499
Sci Immunol. 2020 Aug 21;5(50):
pubmed: 32826343
BMJ Case Rep. 2020 Jun 30;13(6):
pubmed: 32606105
Microbiol Spectr. 2021 Sep 3;9(1):e0016321
pubmed: 34287033
J Glob Health. 2020 Dec;10(2):020504
pubmed: 33110587
Int J Infect Dis. 2020 Aug;97:236-239
pubmed: 32565366
J Microbiol Immunol Infect. 2020 Jun;53(3):404-412
pubmed: 32173241
Virus Res. 2020 Aug;285:198005
pubmed: 32408156
Intensive Care Med. 2020 Sep;46(9):1769-1771
pubmed: 32514592
Sci China Life Sci. 2020 Apr;63(4):606-609
pubmed: 32170625
Med Sci Monit. 2021 Jan 03;27:e929783
pubmed: 33388738
J Infect. 2020 Jul;81(1):147-178
pubmed: 32209381
J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620953282
pubmed: 32862704
JAMA. 2020 May 26;323(20):2085-2086
pubmed: 32293646
J Med Virol. 2020 Nov;92(11):2657-2665
pubmed: 32497283
J Mol Biol. 2006 Dec 15;364(5):964-73
pubmed: 17054987
J Med Virol. 2021 Sep;93(9):5310-5322
pubmed: 34032294
J Med Virol. 2020 Oct;92(10):1785-1786
pubmed: 32293743
J Med Virol. 2020 Nov;92(11):2319-2321
pubmed: 32410338
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
Clin Microbiol Infect. 2020 Sep;26(9):1280-1282
pubmed: 32454188
Crit Care. 2019 Jun 12;23(1):214
pubmed: 31189475
J Med Virol. 2020 Oct;92(10):1699-1700
pubmed: 32352574
J Med Virol. 2021 Apr;93(4):2385-2395
pubmed: 33331656
JAMA. 2020 May 19;323(19):1969-1971
pubmed: 32275293